Monod-Wyman-Changeux allosteric mechanisms of action and the pharmacology of etomidate

Current Opinion in Anaesthesiology

Volumn 25, Issue 4, 2012, Pages 411-418

  Forman, Stuart A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

allosteric model; co agonism; equilibrium; general anesthetic; Gibbs free energy; mutation

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA1; 4 AMINOBUTYRIC ACID A RECEPTOR BETA2; 4 AMINOBUTYRIC ACID A RECEPTOR GAMMA2; ETOMIDATE; ION CHANNEL;

ALLOSTERISM; CONCEPTUAL FRAMEWORK; DRUG BINDING SITE; DRUG EFFICACY; DRUG RECEPTOR BINDING; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; REVIEW; STATISTICAL MODEL; STRUCTURE ACTIVITY RELATION; SYNAPSE; VOLTAGE CLAMP;

ALLOSTERIC REGULATION; ANESTHETICS, INTRAVENOUS; ANIMALS; ETOMIDATE; GABA AGONISTS; HUMANS; MODELS, BIOLOGICAL; MUTATION; RECEPTORS, GABA-A; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84863794950     PISSN: 09527907     EISSN: 14736500     Source Type: Journal    
DOI: 10.1097/ACO.0b013e328354feea     Document Type: Review

References (27)

1. Franks NP, Lieb WR. Is membrane expansion relevant to anaesthesia? Nature 1981; 292:248-251.
2. Franks NP, Lieb WR. Do general anaesthetics act by competitive binding to specific receptors? Nature 1984; 310:599-601.
3. Grasshoff C, Rudolph U, Antkowiak B. Molecular and systemic mechanisms of general anaesthesia: The 'multisite and multiple mechanisms' concept. Curr Opin Anaesthesiol 2005; 18:386-391.
4. Solt K, Forman SA. Correlating the clinical actions and molecular mechanisms of general anesthetics. Curr Opin Anaesthesiol 2007; 20:300-306.
5. Forman SA. Clinical and molecular pharmacology of etomidate. Anesthesiology 2011; 114:695-707.
6. Violet JM, Downie DL, Nakisa RC, et al. Differential sensitivities of mammalian neuronal and muscle nicotinic acetylcholine receptors to general anesthetics. Anesthesiology 1997; 86:866-874.
7. Husain SS, Ziebell MR, Ruesch D, et al. 2-(3-Methyl-3H-diaziren-3-yl) ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate: A derivative of the stereoselective general anesthetic etomidate for photolabeling ligand-gated ion channels. J Med Chem 2003; 46:1257-1265.
8. Belelli D, Muntoni AL, Merrywest SD, et al. The in vitro and in vivo enantioselectivity of etomidate implicates the GABAA receptor in general anaesthesia. Neuropharmacology 2003; 45:57-71.
9. Belelli D, Lambert JJ, Peters JA, et al. The interaction of the general anesthetic etomidate with the gamma-aminobutyric acid type A receptor is influenced by a single amino acid. Proc Natl Acad Sci USA 1997; 94:11031-11036.
10. Jurd R, Arras M, Lambert S, et al. General anesthetic actions in vivo strongly attenuated by a point mutation in the GABA(A) receptor beta3 subunit. FASEB J 2003; 17:250-252.
11. Reynolds DS, Rosahl TW, Cirone J, et al. Sedation and anesthesia mediated by distinct GABA(A) receptor isoforms. J Neurosci 2003; 23:8608-8617.
12. Li GD, Chiara DC, Sawyer GW, et al. Identification of a GABAA receptor anesthetic binding site at subunit interfaces by photolabeling with an etomidate analog. J Neurosci 2006; 26:11599-11605.
13. Bocquet N, Nury H, Baaden M, et al. X-ray structure of a pentameric ligandgated ion channel in an apparently open conformation. Nature 2009; 457: 111-114.
14. Hibbs RE, Gouaux E. Principles of activation and permeation in an anionselective Cys-loop receptor. Nature 2011; 474:54-60.
15. Rüsch D, Zhong H, Forman SA. Gating allosterism at a single class of etomidate sites on alpha1beta2gamma2L GABA-A receptors accounts for both direct activation and agonist modulation. J Biol Chem 2004; 279:20982-20992.
16. Changeux JP, Edelstein SJ. Allosteric mechanisms of signal transduction. Science 2005; 308:1424-1428.
17. Hill-Venning C, Belelli D, Peters JA, Lambert JJ. Subunit-dependent interaction of the general anaesthetic etomidate with the gamma-aminobutyric acid type A receptor. Br J Pharmacol 1997; 120:749-756.
18. Monod J, Wyman J, Changeux J. On the nature of allosteric transitions: A plausible model. J Mol Biol 1965; 12:88-118.
19. Chang Y, Weiss DS. Allosteric activation mechanism of the alpha1beta2-gamma2 gamma-aminobutyric acid type A receptor revealed by mutation of the conserved M2 leucine. Biophys J 1999; 77:2542-2551.
20. Baumann A, Baur R, Sigel E. Individual properties of the two functional agonist sites in GABA(A) receptors. J Neurosci 2003; 23:11158-11166.
21. Findlay GS, Ueno S, Harrison NL, Harris RA. Allosteric modulation in spontaneously active mutant gamma-aminobutyric acid A receptors. Neurosci Lett 2001; 305:77-80.
22. Galzi JL, Edelstein SJ, Changeux J. The multiple phenotypes of allosteric receptor mutants. Proc Natl Acad Sci USA 1996; 93:1853-1858.
23. Scheller M, Forman SA. Coupled and uncoupled gating and desensitization effects by pore domain mutations in GABA(A) receptors. J Neurosci 2002; 22:8411-8421.
24. Stewart DS, Desai R, Cheng Q, et al. Tryptophan mutations at azi-etomidate photo-incorporation sites on a1 or b2 subunits enhance GABAA receptor gating and reduce etomidate modulation. Mol Pharmacol 2008; 74:1687-1695.
25. Forman SA, Stewart D. Mutations in the GABA-A receptor that mimic the allosteric ligand etomidate. In: FENTON AW, ed. Allostery: Methods and protocols. New York, NY: HUMANA Press; 2011. pp. 317-334.
26. Desai R, Ruesch D, Forman SA. Gamma-amino butyric acid type A receptor mutations at beta2N265 alter etomidate efficacy while preserving basal and agonist-dependent activity. Anesthesiology 2009; 111:774-784.
27. Ruesch D, Neumann E, Wulf H, Forman SA. An allosteric coagonist model for propofol effects on alpha1beta2gamma2L gamma-aminobutyric acid type A receptors. Anesthesiology 2012; 116:47-55.